ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Constellation Pharmaceuticals
Start Date
March 5, 2019
End Date
February 28, 2024
Administered By
Duke Cancer Institute
Awarded By
Constellation Pharmaceuticals
Start Date
March 5, 2019
End Date
February 28, 2024